Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Communications Medicine|June 16, 2025
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosisAndreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde, et al.Advances in Radiation Oncology|June 16, 2018
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapyHanne A Eide, Ingerid Skjei Knudtsen, Vandana Sandhu, et al.Molecular Oncology|July 9, 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trialsNikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, et al.Oncoimmunology|February 5, 2019
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristicsShakila Jabeen, Jaime A Espinoza, Lilly Anne Torland, et al.Oncoimmunology|November 1, 2018
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumabShakila Jabeen, Manuela Zucknick, Marianne Nome, et al.Cancer Immunology Research|February 21, 2018
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen ReceptorsVincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, et al.Frontiers in Oncology|May 20, 2026
CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockadeIeva Ailte, Sudhir Kumar Chauhan, Lina Prasmickaite, et al.Journal for Immunotherapy of Cancer|January 19, 2024
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trialNikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, et al.Nature Medicine|December 9, 2022
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trialAndreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Annette Bjerre, et al.Nature Communications|December 5, 2019
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironmentXavier Tekpli, Tonje Lien, Andreas Hagen Røssevold, et al.Pageof 5